Universitaetsklinikum Wuerzburg AöR
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
At Universitaetsklinikum Wuerzburg AöR, research in Hemic and Lymphatic Diseases focuses on blood cancers such as acute myeloid leukemia and multiple myeloma. The trials are designed to evaluate new treatment options, improve disease control, and better understand how emerging therapies may help patients with relapsed or hard-to-treat disease.
- Studies in hematologic malignancies including AML and multiple myeloma
- Research aimed at testing new therapies for relapsed and refractory disease
- Clinical work exploring better ways to improve treatment effectiveness and patient outcomes
The site’s interdisciplinary study center supports trials that look for safer and more effective approaches for patients with advanced blood cancers.
Neoplasms
Clinical research at the Interdisziplinäres Studienzentrum mit ECTU also covers a broad range of neoplasms, including small cell lung cancer, solid tumors, hepatocellular carcinoma, and other advanced cancers. These studies are focused on evaluating innovative therapies, comparing them with standard care, and improving survival outcomes in difficult-to-treat malignancies.
- Trials in oncology spanning lung cancer, liver cancer, and other advanced solid tumors
- Studies assessing whether new treatments can extend overall survival or reduce recurrence
- Research on treatment options for metastatic and refractory cancers
Overall, the research portfolio at this hospital reflects a strong emphasis on testing novel cancer therapies and improving care for patients with advanced disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 12 therapeutic areas and 15 of 109 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 101 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Wuerzburg AöR
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma | AbbVie Deutschland GmbH & Co. KG | Phase I | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 109 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 5 | Unknown | 2025-06-12 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.